LOXO-RAS-20001; A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502756-31-00

Acronym

LOXO-RAS-20001

Enrollment

200

Registered

2024-10-07

Start date

2022-07-20

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

KRAS G12C-Mutant Advanced Solid Tumors

Brief summary

Dose limiting toxicity (DLT) rate and DLT-equivalent toxicities, Rates of TEAEs, SAEs, deaths, and clinical laboratory abnormalities, Antitumor activity of LY3537982

Detailed description

ORR, BOR, DOR, TTR, DCR, PFS, OS, Intracranial ORR and DOR, Plasma concentration of LY3537982 as moontherapy and when administered in combination: PK parameters including, but not limited ot, AUC, Cmax, Tmax, and degree of accumulation

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGCETUXIMAB

DRUGolomorasib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Dose limiting toxicity (DLT) rate and DLT-equivalent toxicities, Rates of TEAEs, SAEs, deaths, and clinical laboratory abnormalities, Antitumor activity of LY3537982	—

Secondary

Measure	Time frame
ORR, BOR, DOR, TTR, DCR, PFS, OS, Intracranial ORR and DOR, Plasma concentration of LY3537982 as moontherapy and when administered in combination: PK parameters including, but not limited ot, AUC, Cmax, Tmax, and degree of accumulation	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026